Objective To investigate the therapeutic effect and mechanism of irisin on diabetic osteoporosis.Methods Diabetic osteoporosis model was established in 6-week-old C57BL/6 mice with intraperitoneal injection of irisin.Body weight,fasting blood glucose,and glucose tolerance tests were conducted.Serum of mice was collected to detect the levels of irisin,CTX,and P1NP.The mRNA expression levels of Runx2,Il-1β,and Il-6 were detected in bone tissue and bone marrow mesenchymal stem cells.The distal femur was collected and stained with HE to quantify the parameters related to bone fine structure.Results After irisin treatment,the diabetic osteoporosis model mice exhibited noteworthy reduction in body weight and fasting blood glucose levels.Additionally,there was a significant rise in irisin concentration in the serum,accompanied by a substantial decrease in CTX concentration and a marked increase in P1NP concentration.Within the bone tissue,the mRNA expression of Runx2 exhibited a pronounced increase,while the mRNA expressions of Il-1β and Il-6 experienced significant decreases.Primary bone marrow mesenchymal stem cells similarly displayed a substantial increase of Runx2 mRNA expression and significant reduction of Il-1β and Il-6 mRNA expression.Furthermore,a noticeable but controlled augmentation was observed in the number of osteoblasts per unit length of bone trabeculae,the percentage of bone trabecular area,and the width of bone trabeculae within the mouse femur.Conclusion Irisin prevents and treats diabetic osteoporosis.The potential mechanism may be to inhibit the expression of inflammatory factors in the bone tissue and mesenchymal stem cells and to promote osteogenic differentiation.
维普
万方数据